| Literature DB >> 25881018 |
Philipp Freislederer1, Michael Reiner2, Winfried Hoischen3, Anton Quanz4, Christian Heinz5, Franziska Walter6, Claus Belka7, Matthias Soehn8.
Abstract
BACKGROUND: Knowing the technical characteristics of gated radiotherapy equipment is crucial for ensuring precise and accurate treatment when using techniques such as Deep-Inspiration Breath-Hold and gating under free breathing. With one of the first installations of the novel surface imaging system Catalyst™ (C-RAD AB, Sweden) in connection with an Elekta Synergy linear accelerator (Elekta AB, Sweden) via the Elekta Response Interface, characteristics like dose delivery accuracy and time delay were investigated prior to clinical implementation of gated treatments in our institution.Entities:
Mesh:
Year: 2015 PMID: 25881018 PMCID: PMC4387684 DOI: 10.1186/s13014-015-0376-x
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1Left: Image of the build-up for the dynamic moving phantom. The surface is reconstructed using mask material. Right: The phantom as it is perceived by the Catalyst™ software.
Figure 2The custom-built extension for the film measurements. Here the extension is placed on the moving rod of the phantom and is moved only in the horizontal direction (red arrow).
Figure 3Left: Ideal case with the absence of time delay. The blackening of the film on the bottom has the exact length of the desired irradiation. Right: Real case with system latency: There is a difference in exposure length between the BEAM-ON signal and the actual exposure of the film (ΔL ) and a difference between the termination signal of the linac and the actual termination of the beam (ΔL ). Both of these can be measured and with a given velocity, the time delay of the system (Δt and Δt ) can therefore be calculated. The schematic blackening of the film on the bottom of each subfigure is a transposition of the film onto the time axis, as ΔL behaves linear proportional to the time delay Δt for given velocities.
Results of the dose measurements for two different field sizes: for both field sizes, there is a decrease in dose relative to ungated treatment when reducing the gating level and therefore increasing the number of start-up processes and delivery time
|
|
|
|
|---|---|---|
| 50% | 99.41 ± 0.07% | 99.59 ± 0.05% |
| 40% | 99.43 ± 0.04% | 99.53 ± 0.04% |
| 30% | 99.45 ± 0.52% | 99.46 ± 0.04% |
| 20% | 98.81 ± 0.05% | 99.09 ± 0.05% |
| 10% | 97.85 ± 0.04% | 98.28 ± 0.05% |